WELCOME TO The PHARMACEUTICAL REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
OBI Pharma | September 14, 2020
OBI Pharma, Inc, a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, today announced a scientific presentation will be held for OBI-999 (anti-Globo H targeted ADC) at the World ADC Digital Scientific meeting on Sept 16, 2020. The scientific presentation titled, "A Novel Globo H-targeting Antibody-drug Conjugate: OBI 999" with a follow-up live discussion and question session will be l...
Long Island University | March 23, 2022
Long Island University announced a new research and innovation partnership with Dassault Systèmes in life sciences. The partnership will focus on research with high societal impact to advance the fields of pharmaceutical sciences, precision medicine and health care in the digital age.
Research includes precision medicine using "Virtual Twins," or exact digital models of human anatomy being developed by LIU and Dassault Systèmes; pandemic preparedness and th...
Yangtze River Pharmaceutical, TraceLink | May 06, 2021
TraceLink Inc., the leading digital network platform company, today announced that Yangtze River Pharmaceutical Group has selected TraceLink's global compliance solution to aid its plans for global growth. As the company gears up for international market expansion this year, Yangtze River Pharmaceutical Group (YRPG) will use TraceLink's multienterprise compliance applications and industry-leading digital supply network to comply with track and trace requirements in multiple markets, incl...
Bloomberg Law | February 13, 2020
Novartis AG is demanding that its 22 “preferred” Big Law firms make specific diverse staffing commitments for each engagement with the pharma giant or face punishment in the form of reduced payments. Through the new program announced on Wednesday, Novartis is also requiring its outside counsel to commit that at least 30% of billable associate time and 20% of partner time will be provided by women, racially or ethnically diverse professionals, or members of the LGBT community. If firm...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE